床旁出生即检即治对HIV感染婴儿临床结局的影响:莫桑比克和坦桑尼亚的整群随机试验
在莫桑比克和坦桑尼亚开展的整群随机试验,将卫生机构分配为干预组(出生时及4-8周提供床旁检测和抗逆转录病毒治疗)或对照组(4-8周开始)。共纳入6602名新生儿,125名在12周内确诊HIV。出生即检即治未显著减少18个月内的临床事件(aIRR 0.857,95%CI 0.505-1.492),但6个月死亡率相对降低68%。病毒抑制整体较差。
要点
- 出生时床旁检测和治疗在资源匮乏地区可行。
- 出生即检即治与6个月死亡率相对降低68%相关。
- 临床结局改善未持续至18个月,病毒抑制整体较差。
核心结论
- 出生时床旁检测和治疗在资源匮乏地区可行,并带来早期死亡率的临床相关降低,但临床结局改善未持续至18个月。
- 病毒抑制较差可能削弱早期获益,呼吁更好的儿科治疗和依从性干预。
研究设计与样本
- 整群随机试验,将卫生机构分配至干预组(出生时及4-8周提供床旁检测和抗逆转录病毒治疗)或对照组(4-8周开始)。
- 2019年10月至2021年9月共纳入6602名新生儿,125名在12周内确诊HIV。
主要发现
- 干预组69名HIV阳性婴儿中38名(55.1%)在出生时确诊;对照组56名中27名(48.2%)回顾性检测为出生时HIV阳性,其中6名(10.7%)在检测前死亡或失访。
- 抗逆转录病毒治疗启动中位年龄:干预组6天 vs 对照组33天。
- 18个月内临床事件:干预组53例(76.8%) vs 对照组48例(85.7%),aIRR 0.857(95%CI 0.505-1.492),无显著差异。
- 6个月死亡率相对降低68%。
局限性
- 病毒抑制整体较差,可能削弱早期获益。
- 临床结局改善未持续至18个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We assessed the impact of point-of-care (PoC) test-and-treat at birth on clinical outcomes and viral suppression among human immunodeficiency virus (HIV)-positive infants in Mozambique and Tanzania. METHODS: This cluster-randomized trial allocated health facilities to intervention, providing PoC testing and antiretroviral treatment (ART) at birth and week 4-8, or control, starting these at week 4-8. The primary outcome was proportions of clinical events (mortality, morbidity, retention, virological failure, toxicity) among HIV-positive infants at month 18. We estimated incidence rate ratios adjusted for timing of HIV detection (aIRR) and reported viral suppression <1000 copies/mL. RESULTS: Among 6602 neonates enrolled during October 2019-September 2021, 125 were diagnosed with HIV by week 12. In the intervention arm, 38 of 69 (55.1%) were diagnosed at birth. In the control arm, 27 of 56 (48.2%) were retrospectively detected to be HIV-positive at birth, of whom 6 of 56 (10.7%) died or were lost to follow-up before testing. Median age at ART initiation was 6 (intervention) versus 33 days (control). Birth test-and-treat was not associated with a significant reduction in clinical outcomes up to month 18 (53 [76.8%] vs 48 [85.7%]; aIRR, 0.857 [95% confidence interval, .505-1.492]), but showed a 68% relative reduction in 6-month mortality. Viral suppression was poor overall. CONCLUSIONS: PoC test-and-treat at birth is feasible in resource-poor settings and resulted in clinically relevant reduction of early mortality, though improved clinical outcomes were not sustained to month 18. Poor viral suppression may undermine early benefits, calling for better pediatric treatments and adherence interventions. Clinical Trials Registration. NCT04032522.
引用
- Jani IV, Sabi I, Elsbernd K, et al. Impact of Point-of-Care Birth Test-and-Treat on Clinical Outcomes Among Infants With HIV: A Cluster-Randomized Trial in Mozambique and Tanzania. Clin Infect Dis. 2025. PMID: 39514367. doi:10.1093/cid/ciae530
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。